Fresenius SE & Co. KGaA

Fund Information / Factsheet • Aug 9, 2016

Factsheet H1 / 2016

COMPANY PROFILE

Fresenius is a global health care group providing products and services for dialysis, hospitals and outpatient medical care. In addition, Fresenius focuses on hospital operations. We also manage projects and provide services for hospitals and other health care facilities. More than 220,000 employees have dedicated themselves to the service of health in over 100 countries worldwide.

FRESENIUS GROUP IN FIGURES

€ in millions	H1/ 2016	H1 / 2015	Change	FY / 2015
Sales and Earnings
Sales	14,006	13,429	4%	27,626
EBIT 1	2,010	1,822	10%	3,958
Net income 1, 2	755	642	18%	1,423
Earnings per ord. share in € 1, 2	1.38	1.18	17%	2.61
Balance sheet and cash fl ow
Total assets	43,821		2%	42,959
Non-current assets	32,821		1%	32,480
Equity 3	18,458		3%	18,003
Equity ratio 3	42%		--	42 %
Net debt / EBITDA 1, 4, 6	2.62		--	2.68
Investments 5	1,175	805	46%	2,029
Operating cash fl ow	1,330	1,251	6%	3,327
Operating cash fl ow in % of sales	9.5 %	9.3%	--	12.0%
Profi tability
EBIT margin 1	14.4%	13.6%	--	14.3%
Return on equity after taxes (ROE) 1, 2	13.6%	12.2%	--	13.0%
Return on operating assets (ROOA) 1, 6	10.2%	9.7%	--	10.1%
Return on invested capital (ROIC) 1, 6	8.4%	7.8%	--	8.3%
Employees	227,865		2%	222,305

1 2015 before special items

2 Net income attributable to shareholders of Fresenius SE & Co. KGaA

3 Including noncontrolling interest

4 At LTM average exchange rates for both net debt and EBITDA

5 Investments in property, plant and equipment, and intangible assets, acquisitions

6 2016 Pro forma acquisitions

SALES BY REGION Latin America and Others 5% Asia-Pacifi c 10% Europe 38% North America 47% H1 / 2016: €14.0 billion

GROUP STRUCTURE

The operating business comprises the four business segments Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed, all of which are legally independent entities managed by the operating parent company Fresenius SE & Co. KGaA.

31% 1	100%	100%	77%
Fresenius Medical Care	Fresenius Kabi	Fresenius Helios	Fresenius Vamed

As of June 30, 2016

1

BUSINESS SEGMENTS

€ in millions		H1/ 2016	H1 /2015	Change	FY / 2015
	Sales EBIT	7,730 1,059	7,312 942	6% 12%	15,086 2,097
	Sales EBIT 1	2,946 616	2,932 571	0% 8%	5,950 1,189
	Sales EBIT 1	2,912 332	2,774 307	5% 8%	5,578 640
	Sales EBIT	472 16	463 16	2% 0%	1,118 64

1 2015 before special items

• ▶ Fresenius Medical Care is the world's largest integrated provider of products and services for individuals undergoing dialysis because of chronic kidney failure. As of June 30, 2016, Fresenius Medical Care was treating 301,548 patients in 3,504 dialysis clinics.
• ▶ Fresenius Kabi Fresenius Kabi offers intravenously administered generic drugs, clinical nutrition and infusion therapies for seriously and chronically ill patients in the hospital and outpatient environments. The company is also a leading supplier of medical devices and transfusion technology products.
• ▶ Fresenius Helios is Germany's largest hospital operator. HELIOS operates 112 hospitals, thereof 88 acute care clinics (including seven maximum care hospitals in Berlin-Buch, Duisburg, Erfurt, Krefeld, Schwerin, Wiesbaden and Wuppertal) and 24 post-acute care clinics. HELIOS treats more than 4.7 million patients per year, thereof more than 1.3 million inpatients, and operates more than 34,000 beds.
• ▶ Fresenius Vamed manages projects and provides services for hospitals and other health care facilities worldwide. The portfolio ranges along the entire value chain: from project development, planning, and turnkey construction, via maintenance and technical management, to total operational management.

SALES BY BUSINESS SEGMENT

Fresenius SE & Co. KGaA – Investor Relations © Copyright, August 3, 2016 Page 1 / 2

FRESENIUS SHARE / ADR

	Share
Securities code no.	578 560
ISIN	DE0005785604
Ticker symbol	FRE
ADR CUSIP	35804M105
ADR Ticker symbol	FSNUY
Number of shares (June 30, 2016)	546,278,580
Market capitalization (June 30, 2016)	€36.0 billion

RELATIVE SHARE PRICE PERFORMANCE FRESENIUS SHARE VS. DAX

DAX Fresenius share

This release contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive conditions, regulatory reforms, results of clinical trials, foreign exchange rate fl uctuations, uncertainties in litigation or investigative proceedings, and the availability of fi nancing. Fresenius does not undertake any responsibility to update the forward-looking statements in this release.

Fresenius SE & Co. KGaA Registered Offi ce: Bad Homburg, Germany Commercial Register: Amtsgericht Bad Homburg, HRB 11852 Chairman of the Supervisory Board: Dr. Gerd Krick

General Partner: Fresenius Management SE Registered Offi ce: Bad Homburg, Germany Commercial Register: Amtsgericht Bad Homburg, HRB 11673 Management Board: Stephan Sturm (Chairman), Mats Henriksson, Dr. Francesco De Meo, Dr. Jürgen Götz, Rice Powell, Dr. Ernst Wastler Chairman of the Supervisory Board: Dr. Gerd Krick

FRESENIUS GROUP'S SENIOR NOTES

Issuer	ISIN	Volume in million	Coupon	Matu rity
Fresenius SE &Co. KGaA 1	XS1013954646	€ 300	2.375%	2019
Fresenius SE &Co. KGaA 1	XS0759200321	€ 500	4.25%	2019
Fresenius SE &Co. KGaA 1	XS0873432511	€ 500	2.875%	2020
Fresenius SE &Co. KGaA 1	XS1013955379	€ 450	3.00%	2021
Fresenius SE &Co. KGaA 1	XS1026109204	€ 450	4.00%	2024
Fresenius US Finance II, Inc.	USU31436AG04	US\$ 300	4.25%	2021
Fresenius US Finance II, Inc.	USU31436AH86	US\$ 300	4.50%	2023
Convertible bonds
Fresenius SE & Co. KGaA	DE000A1YC3T6	€ 500	0.00%	2019

Bonds of Fresenius Medical Care can be found under www.freseniusmedicalcare.com/en/home/ investors/ credit-relations

1 Issuer substitution as of July 29, 2016, previously Fresenius Finance B. V.

SHARE PERFORMANCE 1

1 month	- 3%
1st half	0%
1 year	+ 14%
5 years	+ 174%
10 years	+ 359%

1 Effective date / closing price: June 30, 2016

GROUP OUTLOOK 2016

	Targets 2016
Sales, growth (in constant currency)	6% – 8%
Net income 1 , growth (in constant currency)	11% – 14%
Capital expenditure	~ 6% of group sales

Net income attributable to shareholders of Fresenius SE & Co. KGaA;

2015 before integration costs (€12 million before tax for hospitals acquired from Rhön-Klinikum AG), before costs for the effi ciency program at Fresenius Kabi (€105 million before tax) and before disposal gains from the divestment of two HELIOS hospitals (€34 million before tax)

For the outlook of the business segments please see the Investor News of August 1, 2016.

FINANCIAL CALENDAR

	Dates
Report on 3rd quarter 2016	October 27, 2016
Annual General Meeting, Frankfurt / Main	May 12, 2017

Please note that these dates could be subject to modifi cations.

CONTACT

1

Fresenius SE & Co. KGaA

Else-Kröner-Straße 1, 61352 Bad Homburg v. d. H. e-mail: ir-fre@fresenius.com Internet: www.fresenius.com

Markus Georgi

Senior Vice President Telephone: ++49 61 72 6 08-24 85 Investor Relations Telefax: ++49 61 72 6 08-24 88

Follow us on twitter and linkedin

$$
\bigtriangledown \text{ @Fresenius_IR folgen} \bigtriangledown
$$